Seneca biopharma, inc. (CUR)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities:
Net loss

-12,812

-8,351

-6,634

-6,701

-5,891

-4,924

-7,920

-6,223

-10,245

-15,665

-17,746

-22,832

-22,036

-21,074

-20,443

-20,861

-22,456

-20,903

-21,641

-20,459

-21,762

-22,628

-20,428

-22,660

-22,160

-19,831

-19,243

-15,134

-11,258

-10,121

-9,962

-10,597

-11,869

-12,518

0

0

0

Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization

133

143

139

148

158

185

216

222

244

289

296

340

364

337

365

355

347

345

343

338

341

348

322

321

285

244

228

235

226

211

201

178

196

187

0

0

0

Share-based compensation expense

618

880

825

665

733

634

836

1,031

1,486

1,769

2,082

2,331

2,497

3,445

3,697

3,923

3,732

2,951

2,802

2,653

2,568

4,320

3,889

4,240

4,295

2,331

2,503

1,983

1,717

1,610

1,646

1,827

2,554

3,333

0

0

0

Warrant inducement expense

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of deferred financing fees and debt discount

-

-

-

-

-

-

-

-

-

59

123

203

205

347

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of deferred financing fees and debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

829

853

887

896

694

462

239

22

0

0

0

0

-

-

-

-

Warrant modification expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,017

5,017

3,071

666

0

0

0

0

-

-

-

-

Gain from change in fair value of warrant obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

334

439

1,117

1,305

965

0

0

0

-

-

-

-

-

-

-

-

(Gain) loss on fair value of liability classified warrants

863

499

1,880

1,796

2,738

3,269

738

3,181

1,461

-1,470

38

-3,179

-2,081

660

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant inducement expense

-

-

-

-

-

-

-

-

-

563

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Expenses related to issuance of liability classified warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

466

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of deferred financing fees and debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Gain from change in fair value of derivative instruments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Trade and other receivables

-218

-272

-100

-308

100

-18

124

473

122

302

24

0

-24

-26

-6

-13

30

-188

-13

-5

-3

215

25

-32

-92

6

6

-0

-130

-231

0

0

0

-

-

-

-

Related party receivable

-

-

-

-343

-334

-62

-60

-59

-58

-53

-51

402

392

477

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses

125

142

49

-102

-52

-32

7

118

-131

-297

-451

-581

-652

-513

-344

-137

687

840

837

454

-185

-191

-142

-139

-78

-125

-85

-73

-84

-164

-196

-41

-39

27

0

0

0

ROU and other assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-322

0

0

0

Other assets

-

-

-

-

-

-

-

4

1

-1

-36

-43

-41

-55

-21

1

-0

13

15

-1

-5

-6

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Accounts payable and accrued expenses

-121

-15

329

323

-85

-36

-627

-1,513

-1,002

-1,522

-1,071

-236

-518

879

0

0

0

-

-

-

-

-

-

-

-

-

0

0

0

-

107

376

843

888

0

0

0

Accrued bonuses

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

514

1,382

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued bonuses

-

-

-

-

-

-

-

0

0

-434

0

0

-287

691

-767

-490

61

-485

0

0

0

-

-

0

0

-

-

-

-

24

80

79

434

129

0

0

0

Other current liabilities

-18

-47

-62

-86

-8

11

-7

-15

-250

-230

-179

-136

-58

-21

17

55

306

253

192

135

-6

-2

24

2

2

2

0

0

0

-

-

-

0

-

-

-

-

Lease and other long term liabilities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long term liabilities

-

-

-

-

-

-

-

-5

-14

-16

-16

-17

-90

-155

-210

-264

-318

-250

-194

-140

-6

-9

-12

-13

-12

-11

0

0

0

-

-

-

0

-

-

-

-

Net cash used in operating activities

-7,267

-7,255

-6,864

-6,631

-7,511

-7,692

-8,320

-9,979

-10,827

-13,416

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Cash flows from investing activities:
Purchases of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,517

5,017

25,039

25,039

25,007

25,007

15,000

15,000

0

0

0

0

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-16,467

-17,700

-18,931

-18,512

-16,106

-13,713

-11,706

-10,702

-9,844

-10,791

-10,591

0

0

0

-

-

-

-

-

-

-

-

Maturity of short-term investments

-

-

-

-

-

5,000

5,000

5,000

10,000

5,000

5,000

5,000

0

7,517

7,517

7,517

7,517

15,007

15,007

25,007

25,007

10,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Patent costs

-

-

-

-

-

-

-

-

-

-

-

-

-

63

36

27

22

67

101

171

293

348

394

427

428

411

383

327

282

215

209

298

268

284

0

0

0

Purchase of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

98

146

178

174

176

163

158

112

207

178

265

234

125

127

15

40

39

39

44

146

196

0

0

0

Net cash provided by investing activities

-

-

-

-

-

4,998

4,999

4,999

4,905

-94

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Cash flows from financing activities:
Net cash (used in) provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14,826

14,834

7,246

9,724

-362

-438

-15,563

-15,580

-15,692

-15,663

-537

0

0

0

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock from warrants exercised, net of issuance costs

-

-

-

-

-

-

-

-

-

3,225

3,225

3,006

2,200

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from the sale of common stock and warrants

-

-

-

-

-

-

-

-

-

5,510

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from warrant exercises

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of common stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments of fees related to prior financing

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments of taxes on stock option exercises

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

426

426

426

426

0

0

0

0

-

-

-

-

-

-

-

-

Proceeds from long-term debt transactions, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,551

7,551

7,551

7,551

0

0

0

0

-

-

-

-

Payments of long-term debt

-

-

-

-

-

-

-

-

-

3,765

4,953

6,109

4,695

4,569

4,536

3,380

2,251

1,154

12

504

1,224

1,929

1,917

1,425

704

0

0

0

0

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock from warrants exercised, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,476

1,794

1,933

5,361

7,176

6,107

6,040

2,601

526

204

0

-0

-0

1,668

0

0

0

Proceeds from issuance of common stock from options exercised

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Proceeds from sale of common stock and warrants, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,298

19,467

22,275

26,102

26,149

7,048

4,241

8,808

8,763

13,685

0

0

0

-

-

-

-

Payment on fees for future financing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

45

42

42

42

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Payments of short-term note payable

399

377

356

349

376

363

350

346

336

326

347

313

218

124

0

0

46

117

187

210

204

175

206

183

175

183

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

13,299

6,589

8,438

1,828

1,801

1,814

-1

5,632

3,964

4,990

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Payments on Note Payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Net cash (used in ) provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,124

-3,102

3,887

9,975

9,885

9,403

22,944

21,825

29,597

32,133

20,524

0

0

0

-

-

-

-

-

-

-

-

Effects of exchange rates on cash

-7

-6

-9

-6

-7

-7

-4

-2

0

-0

-2

-0

-0

-0

-1

-4

-5

-4

-1

-0

0

-0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Effects of exchange rates on cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

6,024

-672

1,562

-4,811

-5,719

-887

-3,326

650

-1,956

-8,520

3,387

-4,686

4,059

10,478

-7,454

2,479

-5,972

-7,802

1,185

-6,583

-4,749

-4,327

-4,456

4,066

5,683

9,402

6,528

8,626

7,515

5,091

5,677

-3,602

-3,402

-6,909

0

0

0

Supplemental disclosure of cash flows information:
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,099

1,191

922

954

913

846

786

762

798

847

838

624

400

176

2

2

0

0

0

-

-

-

-

Cash paid for income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Cash paid for interest

9

8

7

7

7

7

7

-18

-16

118

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Extinguishment of warrant obligations through exercise, expiration and modification

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Issuance of common stock for cashless exercise of options, warrants and RSUs

-

-

-

-

-

-

-

-

-

-

-

-

-

8

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock for cashless exercise of warrants and options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

336

1,208

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Prepayment of services through warrant issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Issuance of common stock for cashless exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Issuance of common stock for cashless exercise of options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Issuance of common stock for fees related to debt issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Prepayment of services through common stock issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Prepayment of services through warrant issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Issuance of common stock for fees related to debt issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Issuance of warrants for fees related to debt issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

Issuance of common stock from executive bonuses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0